Source: Journal of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS HEPÁTICAS, CARCINOMA, USO DE MEDICAMENTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZHU, Andrew X. et al. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, v. 33, n. 6, p. 559-566, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2013.53.7746. Acesso em: 17 out. 2024.APA
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., et al. (2015). Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33( 6), 559-566. doi:10.1200/JCO.2013.53.7746NLM
Zhu AX, Rosmorduc O, Evans TRJ, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre M-A, Jensen M, Meinhardt G, Kang YK. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma [Internet]. Journal of Clinical Oncology. 2015 ; 33( 6): 559-566.[citado 2024 out. 17 ] Available from: https://doi.org/10.1200/JCO.2013.53.7746Vancouver
Zhu AX, Rosmorduc O, Evans TRJ, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre M-A, Jensen M, Meinhardt G, Kang YK. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma [Internet]. Journal of Clinical Oncology. 2015 ; 33( 6): 559-566.[citado 2024 out. 17 ] Available from: https://doi.org/10.1200/JCO.2013.53.7746
